pSivida's Second Phase 3 Study for Durasert™ Three-year Treatment for Posterior Segment Uveitis Maintains Positive Efficacy and Safety Profile at 12 Months

World News: . []

WATERTOWN Mass Feb 07 2018 GLOBE NEWSWIRE -- LINK  Corp NASDAQPSDV ASXPVA a leader in the development of LINK  release drug products and technologies today LINK  that results from the Companys LINK  Phase 3 trial for Duraser...

More news and information about pSivida Corp.

Published By:

Globe Newswire: 21:01 GMT Wednesday 7th February 2018

Published: .

Search for other references to "psivida" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us